HUTCHMED (China) Ltd ADR HCM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
-
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
-
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
-
Hutchmed Enters Licensing Agreement With GSK for Cancer Drug
-
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
-
AstraZeneca, Daiichi Sankyo Get New EU Approval for Breast Cancer Drug
-
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
-
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
Trading Information
- Previous Close Price
- $13.94
- Day Range
- $14.05–14.28
- 52-Week Range
- $9.77–16.33
- Bid/Ask
- $13.00 / $14.31
- Shares Outstanding
- 173.81M
- Market Cap
- $2.44B
- Volume/Avg
- 22,412 / 68,021
Key Statistics
- Price/Earnings (Normalized)
- 5.30
- Price/Sales
- 4.47
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,796
- Website
- https://www.hutch-med.com
Valuation
|
Metric
|
HCM
|
|---|---|
Price/Earnings (Normalized) | 5.30 |
Price/Book Value | 1.94 |
Price/Sales | 4.47 |
Price/Cash Flow | 42.01 |
Price/Earnings
HCM
Financial Strength
|
Metric
|
HCM
|
|---|---|
Quick Ratio | 5.45 |
Current Ratio | 5.64 |
Interest Coverage | — |
Quick Ratio
HCM
Profitability
|
Metric
|
HCM
|
|---|---|
Return on Assets (Normalized) | 2.11% |
Return on Equity (Normalized) | 2.98% |
Return on Invested Capital (Normalized) | 2.74% |
Return on Assets
HCM
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|#j%^f$? | LOCK|>M$r& | $70B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|^H?^SP%w | LOCK|sY><k | $48B | |||
| Haleon PLC ADR
HLN
| LOCK|D<#<w?g | LOCK|$$ | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|N?#gqQ?N | LOCK|jN | $33B | |||
| Viatris Inc
VTRS
| LOCK|&v#h&>% | LOCK|ktv | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|BH | LOCK|%P< | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|&mXPdt< | LOCK|<?& | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|kvbYLw | LOCK|H&@ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|K%Tj$Z | LOCK|@vy$c | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|Gwk>x# | LOCK|g&? | $2B |
United States